United Therapeutics (UTHR) Invested Capital (2009 - 2026)

United Therapeutics has disclosed Invested Capital across 18 years of filings, most recently posting $5.9 billion for Q1 2026.

• Invested Capital for Q1 2026 came in at $5.9 billion, down 15.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.9 billion (down 15.79% YoY), and the FY2025 annual result was $7.1 billion, up 5.22% from the prior year.
• Invested Capital came in at $5.9 billion for Q1 2026 at United Therapeutics, down from $7.1 billion in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $7.2 billion in Q2 2025 to a low of $4.2 billion in Q1 2022.
• The 5-year median for Invested Capital is $6.0 billion (2023), against an average of $5.9 billion.
• Across the five-year window, Invested Capital soared 33.11% in 2023 and declined 15.79% in 2026, its largest moves.
• United Therapeutics' Invested Capital stood at $4.8 billion in 2022, then surged by 33.11% to $6.4 billion in 2023, then grew by 5.63% to $6.7 billion in 2024, then advanced by 5.22% to $7.1 billion in 2025, then decreased by 16.84% to $5.9 billion in 2026.
• The last three Invested Capital figures came in at $5.9 billion (Q1 2026), $7.1 billion (Q4 2025), and $6.6 billion (Q3 2025), per Business Quant data.